Printer Friendly

CAMBRIDGE BIOTECH GRANTS SUBLICENSE TO GENENTECH FOR DEVELOPMENT OF AIDS VACCINE

 CAMBRIDGE BIOTECH GRANTS SUBLICENSE TO GENENTECH
 FOR DEVELOPMENT OF AIDS VACCINE
 WORCESTER, Mass., Dec. 3 /PRNewswire/ -- Cambridge Biotech Corporation (NASDAQ: CBCX) today announced it has granted a sublicense for gp120, a key envelope protein of the AIDS virus HIV-1, to Genentech, Inc. (NYSE: GNE). Cambridge is the exclusive licensee of a Harvard University patent for gp120 and its precursor protein gp160. Genentech becomes the twelfth company to receive a gp120 sublicense from Cambridge, which receives a one-time license fee and royalties on sales. Further terms of the agreement were not disclosed.
 Genentech currently has two product development programs utilizing gp120; one application is an AIDS vaccine and the other is an active immunotherapy for asymptomatic HIV-infected individuals. Both programs are in early human clinical trials.
 Commenting on the sublicense, Cambridge Biotech President and CEO Patrick J. Leonard said, "Genentech's leading position in the field of vaccines and therapeutics reinforces the value of this patent in the Cambridge Biotech portfolio. We are pleased to welcome Genentech to our group of sublicensees."
 Other sublicensees are Abbott Laboratories, Baxter Healthcare Corporation, Becton Dickinson, Behringwerke, Chiron Corporation, Diagnostics Pasteur, IAF Biochem, Pasteur Merieux, Pharmacia ENI Diagnostics, Repligen Corporation, and SmithKline Beecham.
 Cambridge Biotech Corporation is a leader in the development of recombinant technology and a major producer of viral diagnostic screening and confirmatory products. The company utilizes recombinant technology in the development and production of antigens. The company also develops adjuvants and monoclonal antibodies as the basis for diagnostic, vaccine and therapeutic products for humans and animals.
 -0- 12/3/91 R
 /CONTACT: Peter P. Hartman, vice president-finance and CFO of Cambridge Biotech, 508-797-5777, or Mark Cohen of Cameron Associates, 212-683-4545, for Cambridge Biotech/
 (CBCX GNE) CO: Cambridge Biotech Corporation; Genentech, Inc. ST: Massachusetts IN: MTC SU: LIC


KD-JT -- NY007 -- 8659 12/03/91 10:18 EST
COPYRIGHT 1991 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1991 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Dec 3, 1991
Words:303
Previous Article:SPACE NEEDS CONTINUE TO LANGUISH
Next Article:EPE RECEIVES ONE-DAY EXTENSION OF FUEL OIL TRUST CREDIT FACILITY; CONTINUES TO SEEK INTERIM EXTENSION & EXTENSION AS PART OF RESTRUCTURING
Topics:


Related Articles
CAMBRIDGE BIOTECH CORPORATION AND GENENTECH, INC. AGREE TO VACCINE ALLIANCE
CAMBRIDGE BIOTECH CORPORATION ANNOUNCES NEW VICE PRESIDENT OF MEDICAL AFFAIRS
BIOGEN REPORTS SECOND QUARTER 1993 EARNINGS OF $5.6 MILLION VS. $0.7 MILLION IN SECOND QUARTER 1992
BANKRUPTCY COURT GRANTS PATENT LICENSE TO CAMBRIDGE BIOTECH FROM INSTITUT PASTEUR COVERING HIV-1 WESTERN BLOT TEST
CAMBRIDGE BIOTECH CORPORATION ANNOUNCES MANAGEMENT APPOINTMENTS
AQUILA BIOPHARMACEUTICALS, INC. TO BE FORMED BY REORGANIZATION OF CAMBRIDGE BIOTECH CORPORATION; FOCUS ON INFECTIOUS DISEASES AND CANCER
Cambridge Biotech Reorganization Plan, Formation Of Aquila Biopharmaceuticals, Upheld By U.S. District Court
Jobs boost for drugs firm.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters